Aspen Aerogels INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Aspen Aerogels' 2026 proxy statement reveals significant 2025 financial underperformance, including a net loss and missed bonus targets, alongside strategic cost reductions and future growth initiatives in energy and EV thermal barriers.
NYSE
Aspen Aerogels has scheduled its 2025 Annual Meeting to be held virtually on April 30, 2025, and is providing proxy materials to stockholders for voting on key proposals.
NYSE
Aspen Aerogels achieved record consolidated revenue of $452.7 million in 2024, alongside expanded gross profit margins and positive net income, while also announcing changes to its Board of Directors.
NYSE
DEFA14A: Aspen Aerogels Urges Stockholders to Vote For Executive Pay Amidst Strong Financial Performance
Aspen Aerogels encourages stockholders to support the advisory vote on executive compensation, highlighting the company's strong 2023 financial and operational performance and disagreement with proxy advisory firms' recommendations.
NYSE
Aspen Aerogels issues a supplement to its proxy statement to correct an error in the number of outstanding shares of common stock as of April 3, 2024.
NYSE
Aspen Aerogels, Inc. has scheduled its 2024 Annual Meeting to be held virtually on May 30, 2024, and has released proxy materials for stockholder review and voting.
NYSE
DEF 14A: Aspen Aerogels Sets Stage for Growth: Stockholders to Vote on Key Proposals at 2024 Annual Meeting
Aspen Aerogels invites stockholders to its virtual 2024 annual meeting to vote on director elections, auditor ratification, and executive compensation, following a year of significant revenue growth and strategic developments.